Costantino Iadecola, M.D., FAHA, of Weill Cornell Medicine to be recognized with the American Heart Association’s 2021 Basic Research Prize

Embargoed until 7 a.m. CT / 8 a.m. ET Wednesday, Nov. 3, 2021

(NewMediaWire) – November 03, 2021 – DALLAS – The American Heart Association (AHA), a global force for longer, healthier lives, will present its 2021 Basic Research Award to Costantino Iadecola, M.D., FAHA, of Weill Cornell Medicine in New York City, in recognition of his outstanding work in cerebrovascular biology, particularly in the areas of stroke and dementia. He will receive the award during the Presidential Session on Sunday, Nov. 14 during the Association’s Scientific Sessions 2021. The meeting will be fully virtual, Saturday, Nov. 13 through Monday, Nov. 15, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.

Dr. Iadecola is a board-certified neurologist whose research focuses on ischemic brain injury, neurodegeneration and cognitive impairment. He is the director and chair of the Feil Family Brain and Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medicine in New York City. He was selected for the Association’s 2021 Basic Research Award in recognition of his research in the areas of cerebrovascular biology, stroke and dementia.

“Dr. Costantino Iadecola’s ground-breaking research in neurology, including developing the concept of the ‘neurovascular unit’ to better understand the causes of stroke and dementia and opening more possible methods of treatment, makes him a true leader at the forefront of his field, significantly impacting how we think about prevention, diagnosis and treatment of neurovascular and neurodegenerative diseases,” said Association President Donald M. Lloyd-Jones, M.D., Sc.M., FAHA. “I’m thrilled to honor him, his work and his commitment to neurovascular research.”

Dr. Iadecola is recognized to have pioneered and validated the concept of the neurovascular unit, a widely accepted notion that neurons and cerebrovascular cells work together to maintain the health of the brain. This concept inspired new research on mechanisms that regulate cerebral perfusion and on how their failure causes brain diseases. His discovery of the cerebrovascular effects of the amyloid-beta peptide and tau established that neurovascular dysfunction is an early biomarker for Alzheimer’s disease. His research demonstrates a relationship between innate immunity and the deleterious effects of hypertension on neurovascular regulation and cognitive function and found that high-salt diets cause dementia through the Alzheimer protein tau, bridging the age-old gap between neurovascular and neurodegenerative diseases. Dr. Iadecola’s work also details how microbiota of the gut can influence a patient’s susceptibility to ischemic stroke.

“I am honored to receive the Basic Research Prize, which I humbly accept on behalf of my mentors, colleagues and collaborators,” said Dr. Iadecola. “I am grateful to the American Heart Association for the continued support I received since the very beginning of my clinician-scientist career.”

Dr. Iadecola earned his medical degree from the University of Rome, Italy. He first came to the U.S. in the 1980s as a post-doctoral fellow in neurobiology at Weill Cornell Medicine, New York. After completing a neurology residency at New York-Presbyterian/Weill Cornell Medical Center in 1990, he joined the University of Minnesota Medical School as an assistant professor in Neurology before returning to New York City as a professor of neurology and neuroscience at Weill Cornell Medicine, where he has been for the past 20 years.

His work has earned accolades from the AHA, the American Academy of Neurology, the National Institutes of Health and the Alzheimer’s Association. He was previously recognized by the Association with its 2009 Willis Lecture Award, given in recognition of his contributions to the role of prostaglandins and nitric oxide in stroke damage and to the role of cerebral blood vessel dysfunction in Alzheimer’s disease. He won the 2015 Excellence Award in Hypertension Research from the Association in recognition of his research connecting hypertension and Alzheimer’s disease. He was honored again by the Association with a 2019 Distinguished Scientist Award to recognize his research contributions to cardiovascular disease, stroke and dementia. Additionally, in 2011 the Alzheimer’s Association recognized Dr. Iadecola with the Zenith Fellow Award, which is prestigious worldwide recognition in Alzheimer’s research.

His research has been documented in nearly 400 papers published in peer-reviewed journals and he is listed by Clarivate Analytics as one of most highly cited researcher in the world in his field. He has been a guest editor for the Hypertension, Circulation and Proceeding of the National Academy of Sciences journals and a member of the editorial boards for Circulation Research, Journal of Cerebral Blood Flow and Metabolism, Cerebrovascular Diseases, Annals of Neurology, Cellular and Molecular Neurobiology and the International Journal of Stroke. (Note: Hypertension, Circulation and Circulation Research are published by the American Heart Association.)

Additional Resources:

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here

The American Heart Association’s Scientific Sessions 2021 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide. The three-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates in a fully virtual experience Saturday, Nov. 13 through Monday, Nov. 15, 2021. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2021 on social media via #AHA21.

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on, Facebook, Twitter or by calling 1-800-AHA-USA1.


For Media Inquiries:

AHA News Media in Dallas: 214-706-1173;

Michelle Kirkwood: 703-457-7838;

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and